Rhaeos develops FlowSense®, a non-invasive, wireless wearable sensor that assesses shunt flow in hydrocephalus patients within minutes. This technology addresses the challenge of detecting shunt malfunctions, which affects over one million Americans and contributes to significant healthcare costs and high readmission rates.
Funding
$12.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Detecting shunt malfunctions in hydrocephalus patients is challenging with current methods, leading to high emergency department discharge rates, readmissions, and significant healthcare costs. Over one million Americans live with hydrocephalus, and the condition results in a $2 billion annual impact on the US healthcare system.
Solution
Rhaeos develops FlowSense®, a non-invasive, wireless wearable sensor designed to assess shunt flow in hydrocephalus patients rapidly. The device aims to provide a quick and easy method for detecting shunt malfunctions across various care settings, including in-hospital, ambulatory, and in-home environments. By offering a more accessible and efficient diagnostic tool, FlowSense® seeks to reduce the rates of misdiagnosis and readmission associated with hydrocephalus shunt complications. The technology is currently under investigation for use within the United States.
Target Audience
The primary target audience includes healthcare providers and patients involved in the diagnosis and management of hydrocephalus, specifically neurosurgeons, neurologists, and patients with shunted hydrocephalus.
Features
- Non-invasive, wireless wearable sensor for assessing shunt flow
- Rapid assessment of shunt flow within minutes
- Designed for use in various care settings (in-hospital, ambulatory, in-home)